Updated:
Electromedical Technologies, Inc
$EMED challenging toxic pain management w/advanced devices using bio-frequency tech triggering natural healing. | ElectroMedical Technologies assembled a team...
Electromedical Technologies, Inc
$EMED challenging toxic pain management w/advanced devices using bio-frequency tech triggering natural healing. | ElectroMedical Technologies assembled a team of leading scientists from around the world in 2004 with a single mission to improve global wellness by relieving chronic and acute pain. In 2007, with FDA clearance, ElectroMedical delivered the industry’s first intelligent portable bioelectronic medicine therapy device, WellnessPro Plus™, which unlike conventional TENS devices, provides faster longer lasting pain relief. WellnessPro Plus is the premier choice for healthcare professionals, athletes, coaches, medical research facilities and any individual who needs to relieve chronic or acute pain.
General information
Firm type
other
Sector focus
Frequently asked questions
What is the primary product of Electromedical Technologies?
The company's flagship product is the BioWave system, a non-invasive electrotherapy device designed to treat chronic pain through waveform-modulated electrical stimulation. It received FDA 510(k) clearance and is marketed to healthcare providers and directly to patients.
How does Electromedical Technologies generate revenue?
Revenue is generated through direct sales of the BioWave device to clinics and individual customers, as well as rental programs that provide recurring income. The company also sells replacement electrodes and accessories.
What regulatory approvals does the BioWave system hold?
The BioWave system has received FDA 510(k) clearance for marketing in the US as a device for pain relief. This clearance allows the company to sell the device legally for its intended use without needing a pre-market approval.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: